Related Guides
Continue your research with these related independent reviews.
Is There a Wegovy Pill? 2026 Status, OASIS-1 Data & What's Available Now
You've heard about a Wegovy pill. Novo Nordisk did develop one — and the clinical trial data is impressive. But as of May 2026, it has not been FDA-approved. Here's what the science shows, when approval might come, and how to access semaglutide for weight loss today.
Quick answer: No approved Wegovy pill as of May 2026
- No FDA-approved oral Wegovy (branded obesity semaglutide) exists today
- Rybelsus (oral sema) is FDA-approved for type 2 diabetes — NOT obesity
- Oral semaglutide 50mg for obesity is in FDA review after strong OASIS-1 results
- Compounded injectable semaglutide from $99/mo is available now
Semaglutide Formulations: FDA Approval Status (May 2026)
There are multiple semaglutide-based products — and their approval status, indications, and availability differ significantly. Understanding the landscape is the first step.
| Product | Status | Indication | Cost |
|---|---|---|---|
Wegovy (injectable, 2.4mg/week) Novo Nordisk · SubQ injection | FDA Approved (2021) | Obesity + cardiovascular risk reduction | ~$1,300–$1,400/mo (no insurance) |
Rybelsus (14mg oral tablet) Novo Nordisk · Once-daily oral | FDA Approved (2019) | Type 2 diabetes ONLY — NOT obesity | ~$800–$1,000/mo (no insurance) |
Oral semaglutide 50mg (obesity) Novo Nordisk · “Wegovy pill” · Once-daily oral | FDA Review Pending | Obesity / weight management | Not yet available for purchase |
Compounded injectable semaglutide 503A/503B pharmacy · SubQ injection | 503A legal — see note | Obesity (off-label via telehealth Rx) | $99–$249/mo |
Compounded oral/sublingual semaglutide 503A pharmacy · drops, troches | 503A limited — see note | Varies by pharmacy / formulation | Varies; limited bioavailability data |
503A note: FDA enforcement discretion for telehealth-scale compounding of semaglutide copies ended April 1, 2026. 503A pharmacies may still compound patient-specific formulations with documented clinical justification. Confirm availability with your telehealth provider. See our compounded semaglutide guide for full regulatory detail.
OASIS-1 vs STEP-1: Does the Pill Actually Work?
The short answer: yes, the data is compelling. The oral 50mg formulation came remarkably close to matching the injection's weight loss in a head-to-head look at the two trials — despite semaglutide having only ~1% oral bioavailability compared to ~94% for the injection.
Key finding: The oral 50mg semaglutide achieved comparable weight loss to injectable Wegovy (15.1% vs 14.9%) at the same 68-week timepoint. The pill used a 50× higher mg dose to compensate for ~1% oral bioavailability, achieving similar plasma semaglutide concentrations through SNAC absorption technology.
Sources: OASIS-1 trial (Knop et al., NEJM 2023); STEP-1 trial (Wilding et al., NEJM 2021). These are separate Novo Nordisk-sponsored trials with different patient populations and enrollment criteria — not a direct head-to-head randomized comparison between formulations.
The Fasting Problem: A Significant Daily Lifestyle Constraint
The OASIS-1 weight loss numbers are impressive — but they come with a compliance requirement that the injection doesn't have. Oral semaglutide only absorbs properly under strict fasting conditions. Every single morning, for as long as you're on the medication.
Oral semaglutide dosing protocol (required every day)
- Take on a completely empty stomach — first thing after waking
- Use no more than 4 oz (120 mL) of plain water — no coffee, juice, or other beverages
- Wait at least 30 minutes before eating, drinking anything other than water, or taking other medications
- Do this without exception, every day for consistent drug exposure
Research shows that taking oral semaglutide with food reduces absorption by approximately 50–80%. Even drinking coffee within 30 minutes meaningfully reduces plasma drug levels.
Compare that to the injectable: once-weekly subcutaneous injection, taken at any time of day, no fasting required, no morning timing constraint. For patients who are consistent with injection compliance, the practical daily burden strongly favors the injection.
| Factor | Oral Sema (pill) | Injectable Wegovy |
|---|---|---|
| Dosing frequency | Daily | Once weekly |
| Fasting requirement | 30 min daily, every day | None |
| Morning routine impact | Restructures breakfast timing | No impact |
| Coffee before dose | Not allowed | Allowed anytime |
| Compliance forgiveness | Low — missed fast = reduced effect | High — weekly window |
| Travel / schedule disruption | Difficult to maintain protocol | Easy — one shot per week |
Why Can Oral Semaglutide Work at All? (SNAC Technology)
Semaglutide is a peptide — proteins and peptides are normally destroyed by stomach acid and digestive enzymes before they can reach the bloodstream. Novo Nordisk solved this with a specialized absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate). SNAC temporarily raises the local pH in the stomach and forms a protective lipophilic microenvironment around the semaglutide molecule, allowing a small percentage of the dose to cross the gastric mucosa directly into circulation.
The result: ~1% bioavailability compared to ~94% for subcutaneous injection. This is why the oral tablet requires 50mg to match what a 2.4mg injection delivers — and why the fasting protocol is non-negotiable. SNAC is proprietary to Novo Nordisk's formulation; compounded oral semaglutide preparations do not use the same technology and cannot replicate the same absorption profile.
Why the Wegovy Pill Will Likely Cost More Than the Injection
Branded injectable Wegovy already costs approximately $1,300–$1,400/month without insurance. The oral formulation will almost certainly be priced at or above that level for several reasons:
- Novo Nordisk incurred substantial R&D and clinical trial costs specific to the oral formulation — these will be recouped through pricing
- SNAC technology manufacturing is more complex than a standard injectable auto-injector pen
- Daily oral dosing (365 units per year) vs weekly injection (52 units per year) means higher raw material costs even at 1% bioavailability
- Brand drugs maintain premium pricing at launch; there is no incentive to price below the existing injection market
- Compounding pharmacies cannot legally replicate the SNAC formulation, so there is no compounded alternative to the pill
The cost-access gap: Compounded injectable semaglutide ($99–$249/mo) will remain the lower-cost semaglutide option even after the Wegovy pill launches — because the pill cannot be compounded. Patients without insurance coverage for branded GLP-1s will still find injectable compounding to be the most accessible path.
What's Available RIGHT NOW: Compounded Injectable Semaglutide
The Wegovy pill is in FDA review. While you wait — or if you're looking for a lower-cost alternative to branded Wegovy — compounded injectable semaglutide is the practical option. Same active ingredient as Wegovy/Ozempic, once-weekly injection, no fasting required. Prices verified May 2026.
From $99/month
$99/mo auto-refill · $119/mo month-to-month
Lowest verified entry price in our active provider stack. Async physician review (no video visit required), LegitScript-certified, HIPAA-compliant, 2-day shipping. Best for cost-sensitive patients who want to start semaglutide without waiting for the pill approval.
- $99/mo — lowest verified price
- No video visit required
- Ships to most US states (excl. AK)
From $158/month (12-month plan)
$249/mo · 6 mo $175/mo · 12 mo $158/mo
Highest-rated provider in our affiliate stack. Same price across all semaglutide doses — no titration upcharge. Offers both injectable and oral sublingual formats, making it one of the few telehealth providers with a needle-free semaglutide option while the branded pill awaits approval.
- Injectable + oral sublingual available
- Same price at all dose levels
- Highest EPC in Katalys stack ($16.09)
$149 first month / $299 flat ongoing
Intro month $149 · All subsequent months $299 flat
Unique GLP-1 gum format — the only provider in our stack with a daily chew option for patients who want to avoid needles while the Wegovy pill remains unapproved. Also offers traditional compounded injectable semaglutide at a flat rate with no dose-titration upcharges.
- GLP-1 gum format — no needle, no fasting
- Flat-rate $299/mo ongoing (all doses)
- $149 intro first month
$229–$249/month
Compounded sema $229–$249/mo · branded Ozempic/Wegovy also available via insurance
The only provider in our stack offering both compounded and branded GLP-1 options side-by-side — useful if you want to start compounded and eventually switch to branded Wegovy (injectable or pill) once insurance covers it. Also has the broadest wellness menu including NAD+, peptides, and hormones.
- Only provider offering branded + compounded side-by-side
- Insurance pathways for branded Ozempic/Wegovy
- $229–$249/mo compounded — higher than TMates/Strut
Compounded semaglutide is NOT FDA-approved. It is produced under 503A/503B pharmacy frameworks. Pricing verified May 2026 but subject to change. Affiliate disclosure: GLP1CompareHub earns a commission on signups — see affiliate disclosure.
Frequently Asked Questions
Is there a Wegovy pill available in 2026?
No. As of May 2026, there is no FDA-approved Wegovy pill. Wegovy remains an injectable medication (semaglutide 2.4mg, once-weekly subcutaneous injection). Novo Nordisk studied a high-dose oral semaglutide (50mg/day) for obesity in the OASIS-1 trial, and the FDA review is pending — but it has not been approved. Do not confuse this with Rybelsus (oral semaglutide 3/7/14mg), which is approved only for type 2 diabetes, not obesity.
What did the OASIS-1 trial show about the Wegovy pill?
The OASIS-1 trial studied oral semaglutide 50mg/day for obesity management over 68 weeks. Participants achieved approximately 15.1% average body weight reduction, compared to approximately 2.4% in the placebo group. This result closely mirrors the STEP-1 trial for injectable Wegovy 2.4mg/week (approximately 14.9% weight loss at 68 weeks), suggesting comparable efficacy between oral and injectable formats at the studied doses.
When will the Wegovy pill be approved by the FDA?
The FDA review of oral semaglutide 50mg for obesity management is pending as of May 2026. Novo Nordisk submitted the NDA following positive OASIS-1 trial results. FDA PDUFA dates are typically 10–12 months from submission. Confirm current approval status through FDA.gov or your prescribing physician, as this is subject to change.
What is the fasting requirement for oral semaglutide?
Oral semaglutide requires strict daily fasting compliance: take on a completely empty stomach using no more than 4 ounces (120 mL) of plain water, then wait at least 30 minutes before eating, drinking anything other than water, or taking other medications. Even small deviations — such as taking it with coffee or eating within 30 minutes — can reduce drug absorption by 50–80%. This is a significant daily lifestyle constraint compared to a once-weekly injection that requires no fasting.
Can I get compounded oral semaglutide for weight loss?
Compounded pharmacies cannot replicate the branded Wegovy pill formulation. The oral semaglutide tablet uses SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) technology to enhance absorption — this is a proprietary excipient system. Compounded oral or sublingual semaglutide preparations exist, but have not been tested for equivalent bioavailability or efficacy compared to the Novo Nordisk formulation. If you want semaglutide for weight loss now, compounded injectable semaglutide (from $99/mo) is the accessible alternative.
Is compounded injectable semaglutide a good alternative while waiting for the Wegovy pill?
For patients seeking semaglutide-based weight loss now, compounded injectable semaglutide is the most accessible option. It contains the same active ingredient as branded Wegovy/Ozempic injections, is available through telehealth providers without insurance from $99–$249/month, and has the same once-weekly injection schedule as branded Wegovy. It is NOT FDA-approved and is produced under 503A/503B compounding pharmacy frameworks. Always discuss with a prescribing physician before starting.
Related Guides
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.